Valuation: Adaptive Biotechnologies Corporation

Market Cap 3.37B 2.96B 2.75B 2.53B 4.77B 322B 4.87B 32.74B 12.8B 158B 12.66B 12.38B 548B P/E 2026 *
-45.7x
P/E 2027 * -85.8x
Enterprise Value 3.24B 2.84B 2.64B 2.42B 4.58B 309B 4.68B 31.43B 12.29B 152B 12.15B 11.88B 526B EV / Sales 2026 *
11.3x
EV / Sales 2027 * 9.08x
Free-Float
98.07%
Yield 2026 *
-
Yield 2027 * -
1 day-0.19%
1 week-0.80%
Current month-2.00%
1 month+19.43%
3 months+64.35%
6 months+15.12%
Current year+29.43%
1 week 19.77
Extreme 19.7711
22.13
1 month 15.9
Extreme 15.9
22.8
Current year 12
Extreme 12
22.8
1 year 9.96
Extreme 9.9551
22.8
3 years 2.28
Extreme 2.28
22.8
5 years 2.28
Extreme 2.28
40
10 years 2.28
Extreme 2.28
71.25
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 53 2009-09-07
Chief Executive Officer 51 2009-09-07
Director of Finance/CFO 42 2024-04-07
Director TitleAgeSince
Chairman 51 -
Director/Board Member 63 2013-01-31
Director/Board Member 70 2013-11-30
Date Insider Type Main position Quantity % Market Cap.
07-01Fiscal year

Head of Human Resources

120,564 0.0753%
07-01Sell

Founder

-386,240 0.2413%
06-30Sell

Executive/Senior Manager

-487 0.0003%
Change 5-day change 1-year change 3-year change Capi.($)
-0.19%-0.80%+77.83%+177.68% 3.37B
+0.90%+0.70%+112.26%+103.11% 4.55B
+1.08%-0.08%-26.22%-38.11% 2.05B
-4.49%-6.26%+116.04%-48.67% 1.89B
+0.88%-1.47%+42.87%+175.48% 1.47B
+4.43%+5.30%+132.97%-49.20% 898M
-1.90%-3.07%-11.78%+39.46% 880M
+2.24%+3.33%-0.46% - 487M
-2.32%-5.43%-38.25%-19.55% 483M
-13.37%-13.37% - - 195M
Average -1.27%-1.16%+45.03%+42.52% 1.63B
Weighted average by Cap. -0.11%-0.17%+67.91%+72.94%

Financials

2026 *2027 *
Net sales 287M 252M 234M 215M 406M 27.46B 415M 2.79B 1.09B 13.49B 1.08B 1.05B 46.65B 352M 309M 287M 264M 498M 33.67B 509M 3.42B 1.34B 16.54B 1.32B 1.29B 57.2B
Net income -71.88M -63.14M -58.55M -53.85M -102M -6.87B -104M -698M -273M -3.38B -270M -264M -11.68B -37.9M -33.3M -30.87M -28.4M -53.64M -3.62B -54.78M -368M -144M -1.78B -142M -139M -6.16B
Net Debt -135M -118M -110M -101M -191M -12.87B -195M -1.31B -511M -6.32B -505M -494M -21.87B -173M -152M -141M -129M -244M -16.5B -249M -1.68B -656M -8.11B -648M -634M -28.04B
Logo Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corporation is a commercial-stage company. The Company focuses on the field of immune medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its immune medicine platform applies its technologies to read the genetic code of a patient's immune system. It operates through two segments, which include Minimal Residual Disease (MRD) and Immune Medicine. The MRD business focuses on the use of its sensitive, next-generation sequencing (NGS) assay to measure MRD in patients with hematologic malignancies. Its MRD business is comprised of its clonoSEQ clinical diagnostic testing service, offered to clinicians. Its Immune Medicine business focuses on immune-repertoire sequencing, target antigen discovery, data licensing and TCR-antigen prediction models in the identification, validation, development and adoption of products and services.
Employees
624
Date Price Change Volume
26-07-13 US$21.02 -0.19% 1,844,250
26-07-10 US$21.06 -3.39% 1,907,792
26-07-09 US$21.80 +8.13% 3,005,961
26-07-08 US$20.16 -3.17% 2,513,999
26-07-07 US$20.82 -3.16% 2,440,474
Trader
Investor
Global
Quality
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
21.02USD
Average target price
20.57USD
Spread / Average Target
-2.13%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ADPT Stock